Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (NCT07032662)
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.
Who can join: Review the eligibility criteria below.
Location: Site Number - 1612 — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (141 Sites)
Showing the first 25 of 141 sites.
- Site Number - 1612 — Tucson, Arizona
- Site Number - 1618 — Carlsbad, California
- Site Number - 1637 — Mission Hills, California
- Site Number - 1619 — Orange, California
- Site Number - 1607 — Rancho Mirage, California
- Site Number -1608 — San Francisco, California
- Site Number - 1626 — Parker, Colorado
- Site Number - 1621 — New Haven, Connecticut
- Site Number - 1630 — Washington D.C., District of Columbia
- Site Number - 1601 — Washington D.C., District of Columbia
- Site Number - 1603 — Maitland, Florida
- Site Number - 1606 — Miami, Florida
- Site Number - 1617 — Ormond Beach, Florida
- Site Number - 1620 — Port Charlotte, Florida
- Site Number - 1633 — Rockledge, Florida
- Site Number - 1632 — Chicago, Illinois
- Site Number - 1602 — Kansas City, Kansas
- Site Number - 1611 — Nicholasville, Kentucky
- Site Number - 1623 — Boston, Massachusetts
- Site Number - 1625 — Worcester, Massachusetts
- Site Number - 1629 — Detroit, Michigan
- Site Number - 1634 — Las Vegas, Nevada
- Site Number - 1605 — New York, New York
- Site Number - 1627 — New York, New York
- Site Number - 1635 — Chapel Hill, North Carolina
📞 Contact the Study Coordinator
Phone: (800) 797-0414
Email: clinicaltrials@immunovant.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Inflammatory Demyelinating Polyneuropathy
- Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP — Denton, Texas
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Homewood, Alabama
- A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Tampa, Florida
- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP — Birmingham, Alabama
- A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) — Birmingham, Alabama
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP — Birmingham, Alabama
Explore by condition: All Chronic Inflammatory Demyelinating Polyneuropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.